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Positive pressure drug releasing device
Abstract
A positive pressure long-term drug delivery device particularly useful for the intravaginal or intrauterine
release of a drug capable of passing through a diffusion membrane and being absorbed by the vaginal or
uterine epithelium. The device includes a tubular casing having a plunger urged by a compression spring to
create a continuous positive pressure on a drug in liquid form within the chamber of the casing, a supported
membrane at one end of the casing through which such drug diffuses at a predetermined rate, and resilient
elements at the opposite end of the casing for facilitating retention of the device throughout the term of
administration of the drug.
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POSITIVE PRESSURE DRUG RELEASING 
DEVICE 
BACKGROUND AND SUMMARY 
While the device of this invention is applicable for the 
long-term delivery of various drugs to a wide variety of 
animals, not excluding human beings, it is believed par 
ticularly useful for treating domestic animals for the 
purpose of reversibly controlling reproduction. The 
need is particularly acute with regard to control of the 
canine population in view of the increasing number of 
unwanted stray and abandoned dogs in this country and 
elsewhere. Such free-roaming animals have been known 
to cause property damage and attack other animals 
(including man) as well as carrying and spreading dis 
eases. Few methods are presently available for success 
fully controlling canine reproduction. 
Ovariohysterectomy (spaying) constitutes a positive 
method of reproduction control; however, ovariohys 
terectomy has met with opposition because of its irre 
versibility (especially with respect to pets) and because 
of its cost (primarily with respect to stray or abandoned 
animals). As an alternative to spaying, mechanical de 
vices have recently become available which are de 
signed to prevent penile insertion into the female but, 
unfortunately, such devices are of limited effectiveness. 
Chemosterilants have been studied and found to con 
trol fertility, but they often cause pathological changes 
in the uterus making ovariohysterectomy necessary. All 
known exogenous progestens cause cystic endometrial 
hyperplasia, endometritis, and mucometra. Of various 
progestens that have been studied, only magestrol ace 
tate is approved for commercial use and, in addition to 
the disadvantages already mentioned, is relatively ex 
pensive. 
The problems with chemosterilants is not only one of 
drug selection but also of ease and effectivenessv of ad 
ministration. Thus, subcutaneous androgen implants 
such as testosterone have been tested in the bitch and 
found to inhibit estrus with minimum side effects. Im 
plantation is, however, a surgical procedure usually 
requiring the administration of anesthesia and, depend 
ing on the weight of the animal, more than one implant 
may be necessary. Oral administration, although sim 
pler, is time-consuming and inconvenient since estrus is 
inhibited only for the duration of a daily dosage which 
must be initiated prior to the beginning of procstrus to 
be effective. 
Osmotic devices for delivering drugs in various se 
lected environments have been disclosed, for example, 
in US. Pat. Nos. 4,160,452, 4,036,227, and 4,014,334. 
While such devices are intended to deliver drugs at 
continuous and predetermined rates for extended peri 
ods, their effectiveness depends on osmotic pressure 
which in turn depends on factors which may be vari 
able. The presence and extent of ?uid surrounding such 
devices, and the precise nature of such fluid, all affect 
the operation of osmotic devices. 
Other patents indicating the state of the art are US. 
Pat. Nos. 3,659,600, 3,984,263, 3,492,993, 1,476,946, and 
3,929,l32, and the references cited therein. 
In view of the above, it is a main object of this inven 
tion to provide a long-term drug delivery device suit 
able for intrauterine or intravaginal (preferably the 
latter) placement, which is positive-acting in its opera 
tion. Speci?cally, it is an object to provide an intrava— 
ginal or intrauterine device which utilizes a positive 
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pressure mechanism for the gradual and continuous 
delivery of a drug to a warm-blooded animal. 
The positive pressure mechanism includes a compres 
sion spring which exerts a constant force to reduce the 
size of a variable-volume chamber containing a drug 
solution which is capable of passing through a diffusion 
membrane and of being absorbed by the vaginal or 
uterine epithelium. One Wall of the chamber includes a 
supported diffusion membrane; a second wall of the 
chamber, or a compartment of that chamber, takes the 
form of a plunger driven by the compression spring. 
The casing de?ning the chamber is preferably of cylin 
drical shape and is dimensioned to be received within 
the body cavity of the animal to be treated. Where the 
cavity constitutes the vaginal cavity, the device is addi 
tionally provided with ?exible retaining elements which 
project radially outwardly from the end of the casing 
opposite from the end in which the diffusion membrane 
is supported. The result is a dependable and relatively 
simple drug-delivery device which utilizes a positive 
pressure mechanism, not dependent upon osmotic pres 
, sure, and which is particularly suitabie for delivering 
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estrus-controlling drugs to livestock, pets, and other 
warm-blooded animals. 
Other features, objects, and advantages of the inven 
tion will become apparent from the drawings and speci 
?cation. 
DRAWINGS 
FIG. 1 is a perspective view of a device embodying 
this invention. 
FIG. 2 is an exploded fragmentary perspective view 
depicting the various components of the device. 
FIG. 3 is an enlarged exploded perspective view 
illustrating the diffusion membrane and its supporting 
elements. 
FIG. 4 is an enlarged longitudinal sectional view of 
the device illustrating the operative relationship of 
parts. 
DETAILED DESCRIPTION 
Referring to the drawings, the numeral 10 generally 
designates a drug releasing device or capsule having a 
tubular casing 11 de?ning a cylindrical chamber 12. 
One end of the chamber is closed by a threaded plug or 
end wall 13, the inner surface of the chamber being 
threaded to receive the plug. The opposite end of the 
casing is open and receives a supported diffusion mem 
brane assembly 14 (FIG. 3). The assembly 14 includes a 
diffusion membrane 15, a retaining ring 16, and an aper 
tured membrane support member 17. As shown most 
clearly in FIG. 4, the casing 11 is counterbored to pro 
vide a shoulder 18 for bracing the retaining ring 16. The 
membrane 15 is sandwiched between the ring and the 
apertured support member 17, the latter being thread 
edly received within the delivery end of the casing. The 
exposed area of the diffusion membrane 35, and hence 
the diffusion of drug through that membrane, may be 
varied by selecting a ring 16 having a central opening of 
the desired size. 
The membrane support member is provided with a 
plurality of apertures 19 which are parallel with the axis 
of that member and extend completely therethrough. 
While such apertures may perform a secondary func 
tion is providing a means for gripping the member with 
a suitable wrenching device in order to screw it tightly 
into place, the primary function of such apertures is to 
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provide discharge passages for the delivery of a treat 
ment medium to the host animal. Five such apertures 
are shown in the drawings although the number and size 
of such apertures should not be taken as critical. In the 
delivery of a drug, the metering function is performed 
primarily by the diffusion membrane; hence, the num 
ber and total area of the apertures should not be so small 
as to interfere with the metering action of the diffusion 
membrane, nor should they be so large or few in num 
ber that the member 17 fails to provide adequate sup 
port for the membrane. Within such general guidelines, 
the number and size of the apertures 19 may be varied 
considerably. 
Within chamber 12 is a plunger 20 which slidably and 
sealingly engages the cylindrical inner surface of the 
casing. A compression spring 21 is interposed between 
end wall 13 and plunger 20 to provide a constant and 
generally uniform force urging the plunger towards the 
delivery end of the device. 
Within the chamber 12, in the space between plunger 
20 and the diffusion membrane 15, is a drug solution 22. 
The liquid treatment agent may be any of a variety of 
drug solutions capable of diffusing through membrane 
15 and being absorbed by the uterine or vaginal epithe 
lium. The device of this invention is considered particu 
larly useful for the long-term administration of an estrus 
inhibiting drug such as, for example, mibolerone (7 
alpha, l7-dimethyl-19n0rtestosterone), and androgenic 
anabolic steroid; however, the device may be used for 
administering other chemosterilants (such as magestrol 
acetate, chlormadinone, melengestrol acetate, delmadi 
none acetate, noresthisterone acetate, testosterone, etc.) 
as well as steroids and other medicaments for treatment 
of arthritis, hormones for correcting hormonal imbal 
ances (insulin), antibiotics, and the like. With respect to 
the operation of the device, the essential factors are that 
the drug be stable throughout the term of administra 
tion and be capable of diffusing through membrane 15 
and being absorbed through the wall of the body cavity. 
For vaginal implantation the device is provided with 
a resilient sleeve 23 (silicone rubber) which covers the 
side wall of the casing and which is provided at the 
proximal end of the device (the end opposite the deliv 
ery or distal end) with a multiplicity of ?exible ?ngers 
24. The ?ngers 24 extend axially beyond end wall 13 
and ?are radially outwardly. It has been found that the 
spring action of the outwardly ?ared integral ?ngers 24 
is highly effective as retaining means for holding the 
device within the vaginal cavity. The ?ngers ?ex out 
wardly for gently but effectively engaging the vaginal 
epithelium to secure the device in operative position. 
To facilitate removal of the device, an extraction cord 
25 may if desired be secured to the end wall 13 of the 
casing. As shown in FIGS. 1, 2, 4, the plug or end wall 
is provided with an integral loop or ring 26 for attach 
ment of the extraction cord or other removal device. 
The materials from which the device is formed may 
vary considerably, the main requirement being that they 
be durable, function properly, and be non-toxic and 
non-irritating. The cylindrical portion of the casing 11 
may, for example, be stainless steel although polymeric 
materials such as polytetra?uoroethylene may be used. 
Similarly, the retaining ring 16, membrane support 
member 17 and end plug 13 may be formed of a durable 
inert plastic (as shown) or of a metal having similar 
non-reactive properties. Membrane 15 may be formed 
of any suitable polymeric material capable of function 
ing as a diffusion membrane; silicone rubber, preferably 
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reinforced medical grade silicone rubber subdermal 
implant material sold under the designation Silastic 
Sheeting 501-7 by Dow Chemical Company, Midland, 
Michigan, has been found effective but other known 
membrane materials may be used. Silicone rubber is also 
a suitable material for the fabrication of outer sleeve 23 
with its integral spring ?ngers 24 but, again, other poly 
meric materials having similar properties may be se 
lected. 
The rate of delivery of the drug is controlled primar 
ily by the concentration of the drug solution but may 
also be adjusted to varying the thickness and exposed 
area of the membrane and the pressure developed by 
the compression spring, such delivery rate being se 
lected on the basis of the dosage requirements for the 
particular treatment or effect sought to be achieved. 
The spring 21 should exert a substantially constant force 
through the full range of movement of plunger 20. In 
general, that force should develop a pressure upon ?uid 
22 within the range of about 400 to 1500 mm Hg, prefer 
ably 600 to 1200 mm Hg. The effect is to overcome or 
make negligible the back diffusion osmotic pressures 
external to the membrane, assist in maintaining a rela 
tively constant concentration within the device, and 
contribute to providing a substantially constant ?ow 
across the membrane. The effect is revealed by the 
following formula: 
where N is the net ?ow of drug solution i across the 
diffusion membrane, C is the concentration of the drug 
solution, K is the permeability of the membrane, Ap is 
the difference in pressure (i.e., the positive pressure 
generated by the spring plus osmotic pressure from the 
inside of the membrane, to the osmotic pressure (back 
diffusion) from the outside of the membrane), Dim is the 
diffusion coefficient across the membrane, and AZ is the 
change in distance across the membrane. Thus, it is 
evident that the ?ux of a species across the membrane, 
in this case the drug solution, is the sum of a ?ux driven 
by pressure and a ?ux driven by concentration. Stated 
differently, an increase or reduction in the pressure 
created by selecting springs of different strength pro 
duces a generally proportional increase or decrease in 
the ?ow across the membrane, other factors remaining 
constant. Since the helical compression spring exerts a 
substantially constant force and therefore creates a sub 
stantially constant linear pressure, the result, using any 
such spring capable of producing a constant internal 
pressure substantially greater than back diffusion os 
motic pressures, is the achievement of a substantially 
uniform diffusion rate of the drug across the membrane 
over the operating life of the device. While such operat 
ing life would depend primarily on the drug involved 
and the purpose of its administration, in general the 
term would fall within the range of about one week to 
several months or more. 
The invention is further illustrated by the following 
examples: 
EXAMPLE 1 
A device for controlling estrus in dogs was con 
structed generally as shown in the drawings utilizing a 
tubular casing 11 having an outside diameter of 13 mm, 
a chamber diameter of 5 mm and a membrane of silicone 
rubber having a thickness of 1 mm. The membrane 
support member 17 included 5 apertures each having a 
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diameter of 1 mm. The capsule when fully charged 
contains 0.8 ml of ethanol with 8760 micrograms (mcg) 
of mibolerone dissolved therein. Coil spring 21 devel 
oped an internal pressure of about 800 mm Hg. 
EXAMPLE 2 
Fifteen female dogs (beagles) were treated with mi 
bolerone utilizing devices prepared as set forth in this 
application and as speci?ed in Example 1. Each device 
was placed in the vaginal tract of an animal during the 
month preceding the time when, on the basis of calcula 
tions from prior records, the dog was expected to come 
into estrus. The capsules were left in place for periods 
ranging between 10 to 12 weeks. Capsules which were 
removed at 10 weeks had approximately 0.1 ml solution 
left, whereas those removed at 12 weeks generally had 
no drug solution remaining therein. All dogs treated 
remained out of estrus during the periods in which the 
capsules remained vaginally implanted. 
While in the foregoing we have disclosed an embodi 
ment of the invention in considerable detail for purposes 
of illustration, it will be understood by those skilled in 
the art that many of these details may be varied without 
departing from the spirit and scope of the invention. 
We claim: 
1. A positive pressure drug releasing device compris 
ing an elongated casing having a tubular side wall defin 
ing a chamber; said casing being open at one end and 
having an end wall at the other end thereof; a diffusion 
membrane secured to said casing and extending across 
said open end; a plunger slidably disposed within said 
chamber for axial movement therein; a drug solution in 
said chamber between said plunger and said membrane; 
said drug solution being diffusable through said mem 
brane and absorbable by the body wall of a cavity in 
which said device is implanted; and a compression 
spring interposed between said plunger and said end 
wall; said spring being in a state of compression for 
producing a substantially uniform positive pressure on 
said drug solution of a magnitude sufficient to render 
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negligible the effects of back diffusion osmotic pressure 
when the device is in use. 
2. The device of claim 1 in which said compression 
spring is a coil spring capable of expanding from a com 
pressed state to an expanded state within said chamber 
during the term of administration of said drug solution; 
said spring exerting a substantially uniform force over 
such range of expansion to generate a positive pressure 
within said chamber in the range of about 400 to 1500 
mm Hg. 
3. The device of claim 2 in which said spring gener 
ates a positive pressure within said chamber within the 
range of about 600 to 1200 mm Hg. 
4. The device of claims 1, 2, or 3 in which said diffu 
sion membrane is formed of silicone rubber. 
5. The device of claim 1 in which a membrane sup 
port member is secured to said casing external to said 
membrane to brace said membrane against outward 
movement in response to pressure of said solution gen 
erated by said spring; said support member having a 
plurality of apertures extending therethrough and paral 
lel with the longitudinal axis of said device; said aper 
tures being sufficiently large in size to have no substan 
tial adverse effect on the drug-metering action of said 
diffusion membrane. 
6. The device of claims 1, 2, or 3 in which a plurality 
of ?exible ?ngers slope radially outwardly and axially 
away from the end of said casing remote from said 
diffusion membrane for assisting in retaining said device 
within the vaginal tract of a warm-blooded animal. 
7. The device of claim 6 in which said casing has a 
protective sleeve extending thereabout, said ?ngers 
being formed integrally with said sleeve. 
8. The device of claim 8 in which said sleeve and 
?ngers are formed of ?exible non-irritating polymeric 
material. ' 
9. The device of claim 6 in which an extraction cord 
is secured to said end wall between said ?ngers and 
extends from said device in the general axial direction of 
said fingers to facilitate extraction of the device fr 
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